BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23397008)

  • 41. Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma.
    Liang JH; Ding CY; Gale RP; Wang L; Xu J; Qu XY; Fan L; Li TL; Li JY; Xu W
    Oncotarget; 2017 Jan; 8(1):1737-1743. PubMed ID: 27974685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.
    Bakhshi S; Radhakrishnan V; Sharma P; Kumar R; Thulkar S; Vishnubhatla S; Dhawan D; Malhotra A
    Radiology; 2012 Mar; 262(3):956-68. PubMed ID: 22357895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas.
    Song GY; Jung SH; Ahn SY; Kim M; Ahn JS; Lee JJ; Kim HJ; Moon JB; Yoo SW; Kwon SY; Min JJ; Bom HS; Kang SR; Yang DH
    Korean J Intern Med; 2024 Mar; 39(2):327-337. PubMed ID: 38268194
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.
    Han EJ; O JH; Yoon H; Jung SE; Park G; Choi BO; Cho SG
    Medicine (Baltimore); 2016 Sep; 95(39):e4983. PubMed ID: 27684851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas.
    Chan WK; Au WY; Wong CY; Liang R; Leung AY; Kwong YL; Khong PL
    Clin Nucl Med; 2010 Aug; 35(8):571-5. PubMed ID: 20631501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
    Mato AR; Svoboda J; Feldman T; Zielonka T; Agress H; Panush D; Miller M; Toth P; Lizotte PM; Nasta S; Goldberg S; Chong E; Schuster S; Pecora AL; Goy A
    Cancer; 2012 Jul; 118(14):3565-70. PubMed ID: 22180256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
    Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
    Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
    Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interim 18F-FDG PET/CT and BCL2 for predicting the prognosis of patients with diffuse large B-cell lymphoma in the rituximab era.
    Jiang M; Chen P; Ruan X; Xu W; Li T; Wu L; Zhou W; Wu H; Wang Q
    Nucl Med Commun; 2018 Feb; 39(2):147-153. PubMed ID: 29189488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.
    Itti E; Lin C; Dupuis J; Paone G; Capacchione D; Rahmouni A; Haioun C; Meignan M
    J Nucl Med; 2009 Apr; 50(4):527-33. PubMed ID: 19289424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Prognostic value of interim and post-therapy 18F-FDG PET-CT in patients with T-cell lymphomas].
    Wang X; Huang H; Ying Z; Wang X; Song Y; Zheng W; Xie Y; Lin N; Tu M; Ping L; Liu W; Deng L; Zhang C; Yang Z; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):350-2. PubMed ID: 24759028
    [No Abstract]   [Full Text] [Related]  

  • 58. [¹⁸F-FDG PET/CT for predicting outcomes of diffuse large B-cell lymphoma: shall it be performed in the interim versus later phase of chemotherapy?].
    Li H; Wu H; Wang Q; Li H; Zhou W; Tian Y; Dong Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):208-12. PubMed ID: 25736114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.
    Moon SH; Lee AY; Kim WS; Kim SJ; Cho YS; Choe YS; Kim BT; Lee KH
    Leuk Lymphoma; 2017 Jun; 58(6):1341-1348. PubMed ID: 27718766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
    Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
    Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.